DYNACIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DYNACIN (DYNACIN).
Dynacin (minocycline) is a semi-synthetic tetracycline antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to mRNA-ribosome complex. It also has anti-inflammatory and neuroprotective effects via inhibition of microglial activation, matrix metalloproteinases, and p38 MAPK signaling.
| Metabolism | Minocycline is extensively metabolized in the liver via glucuronidation and by hydroxylation of the benzyl ring. Three major metabolites have been identified: 9-hydroxyminocycline, 7-hydroxyminocycline, and M-5 (a glucuronide conjugate). Minor pathways include demethylation and N-dealkylation. It is not significantly metabolized by CYP450 enzymes. |
| Excretion | Renal (40-50% unchanged), hepatic metabolism (30-40% as metabolites), fecal (<10%). |
| Half-life | Terminal elimination half-life 18-24 hours; prolonged in renal impairment (up to 50 hours in severe insufficiency). Steady state achieved in 4-5 days. |
| Protein binding | 70-80% bound to serum proteins (primarily albumin). |
| Volume of Distribution | 0.7-1.5 L/kg; high distribution into tissues including skin, bone, and prostate; doxycycline accumulates in macrophages and inflammatory cells. |
| Bioavailability | Oral: approximately 90-100% absorption; reduced by food (not significant clinically). |
| Onset of Action | Oral: 1-2 hours; IV: within 30 minutes; topical: variable, typically 2-6 weeks for clinical improvement in acne vulgaris. |
| Duration of Action | Oral/IV: 24 hours (once-daily dosing maintains therapeutic levels); topical: prolonged effect due to follicular retention; clinical improvement continues for weeks after cessation. |
| Molecular Weight | 444.43 |
100 mg orally twice daily or 200 mg orally once daily.
| Dosage form | CAPSULE |
| Renal impairment | No adjustment required for mild to moderate renal impairment. For severe impairment (GFR <30 mL/min), reduce dose to 100 mg once daily. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh C). For mild to moderate (Child-Pugh A or B), reduce dose to 100 mg once daily. |
| Pediatric use | Children ≥12 years: 100 mg orally twice daily or 200 mg orally once daily. Children <12 years: not recommended. |
| Geriatric use | No specific dose adjustment required. Use with caution due to increased risk of adverse effects (e.g., photosensitivity, gastrointestinal intolerance). |
| 1st trimester | Use only if clearly needed. Animal studies show risk, but human data limited. Avoid in first trimester if possible. |
| 2nd trimester | May cause fetal bone and tooth discoloration if used after 4 months gestation. Use only if no alternative. |
| 3rd trimester | Contraindicated in third trimester due to risk of fetal bone and tooth discoloration, and potential for hepatotoxicity in pregnant women. |
Clinical note
Comprehensive clinical and safety monograph for DYNACIN (DYNACIN).
| Placental transfer | Crosses placenta. Fetal serum concentrations reach 50-70% of maternal levels. |
| Breastfeeding | Excreted into breast milk in low concentrations. Theoretical risk of bone and tooth discoloration in nursing infants. Use caution, especially in prolonged or repeated courses. Alternative antibiotics preferred. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to minocycline or any tetracyclinePregnancy (especially third trimester)Lactation (prolonged use)Children under 8 years (except for anthrax, RMSF, or other severe infections)
| Precautions | Hepatotoxicity: Rare but serious; monitor liver function. Cases of autoimmune hepatitis with minocycline., Permanent tooth discoloration (avoid in children <8 years unless other drugs not likely effective or contraindicated)., Pseudotumor cerebri (intracranial hypertension): Risk with minocycline; discontinue if symptoms (headache, blurred vision, diplopia) occur., Photosensitivity: Exaggerated sunburn risk; avoid excessive sunlight/tanning., Superinfection (including C. difficile diarrhea)., Use in renal impairment: May accumulate; dose adjustment recommended (CrCl <80 mL/min)., Lupus-like syndrome, serum sickness-like reactions reported., Neurologic effects: Dizziness, vertigo, ataxia (commonly occurs; caution when driving)., Bone growth inhibition (avoid in premature infants and children <8 years)., Thyroid dysfunction: Monitor thyroid function with prolonged use. |
| Food/Dietary |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | DYNACIN (minocycline) is classified as FDA Pregnancy Category D. Tetracyclines cross the placenta and may cause fetal harm. First trimester: No increased risk of major malformations from limited human data. Second and third trimesters: Exposure may cause permanent discoloration of deciduous teeth (yellow-gray-brown) if administered during dental development (from 4th month of gestation). Risk of reversible inhibition of fetal skeletal growth due to binding to calcium in bone. Animal studies show embryotoxicity and teratogenicity at high doses. |
| Fetal Monitoring | Monitor maternal liver function tests, renal function, and blood counts during prolonged therapy. If used in pregnancy, monitor fetal development with ultrasound and consider serial growth assessments due to risk of skeletal growth retardation. Monitor for signs of hepatotoxicity or pancreatitis in the mother. |
| Fertility Effects | Minocycline may impair fertility in males and females based on animal studies. In humans, case reports suggest reversible infertility due to sperm motility impairment or menstrual irregularities. Cautious use in patients planning pregnancy. |
| Avoid concurrent ingestion of dairy products (milk, cheese, yogurt) and calcium-fortified foods within 2-3 hours of dosing. Do not take with antacids, bismuth subsalicylate, or iron/zinc/calcium/magnesium supplements. Alcohol is not contraindicated but may increase risk of hepatotoxicity. |
| Clinical Pearls | Dynacin (minocycline) is a tetracycline antibiotic with high lipophilicity, allowing excellent tissue penetration including CNS. It is a first-line for acne vulgaris due to anti-inflammatory properties beyond antibacterial. Avoid in children <8 years and pregnancy due to permanent tooth discoloration and bone growth inhibition. Monitor for hepatotoxicity and vestibular toxicity (dizziness, ataxia). |
| Patient Advice | Take with a full glass of water to reduce esophageal irritation. · Avoid dairy products, antacids, iron, calcium, magnesium, and zinc supplements within 2-3 hours of dosing as they reduce absorption. · Do not take just before bedtime; remain upright for at least 30 minutes after dosing. · Report any symptoms of severe headache, dizziness, or visual disturbances (pseudotumor cerebri). · Use sun protection (SPF 30+ sunscreen and protective clothing) as photosensitivity occurs. · Complete the full course even if symptoms improve; do not double missed doses. · Store at room temperature, protect from light and moisture. |